23 September 2019
IntegraGen announces 2019 first half results: Continued improvement in profitability
30 June 2019
Press release on General Assembly voting results
The mixed shareholders’ general meeting of IntegraGen was held on Thursday, June 13, 2019 at the Bedford Hotel’s premises at 17 rue de l’Arcade in Paris.
At the end of the Combined General Meeting, (…) »
18 April 2019
IntegraGen Reports 2018 Annual Results
IntegraGen has announced the company’s financial results for the year ending December 31, 2018. The annual accounts were approved by the Board of Directors held on April 17, 2019.
Click here to view press release.
15 March 2019
IntegraGen to present at 6th annual Portzamparc MidCap Conference – April 10, 2019
Come and meet us at the #ConfMidCap2019 @Portzamparc, April 10th!
05 March 2019
IntegraGen and Advanced Biological Laboratories sign global licensing agreement for the commercialization of miRpredX test
IntegraGen and Advanced Biological Laboratories (ABL) have announced the signing of a non-exclusive global licensing agreement enabling ABL to distribute miRpredX™, IntegraGen’s proprietary IVD CE marked diagnostic test that enables clinicians to identify metastatic colorectal cancer patients who have a higher likelihood of response to anti-EGFR therapy.
09 January 2019
IntegraGen Reports Revenue of €6.9 million for 2018 (+11%) and Cash Position of €4.0 million
IntegraGen announced today its unaudited annual sales revenue for 2018.
Sales revenue of €6.9 million (+11%) Very strong increase (+29%) in sequencing services for the R&D segment Strong reduction in cash consumption. Cash position of €4.0 million as of December 31, 2018 Commercial launch of SIRIUS and MERCURY online genomic data (…) »12 November 2018
IntegraGen Announces Collaboration with Google Cloud to Offer Large Scale Genomic Analysis Tools for Clinicians and Medical Researchers
IntegraGen has announced it is collaborating with Google Cloud for the implementation of IntegraGen’s advanced genomic analysis tools, SIRIUS™ and MERCURY™ into the Google Cloud Platform. This partnership will enable widespread online availability, rapid data transfer and enhanced data security to clinicians and researchers utilizing these analytical tools.
(…) »21 October 2018
IntegraGen presents new data expanding application of miR-31 to stage III colon cancer during ESMO 2018
Analysis of PETACC-8 clinical trial samples demonstrates company’s proprietary miR-31 microRNA biomarkers identifies subpopulations of patients with resected stage III colon cancer who benefit from the addition of cetuximab to FOLFOX adjuvant therapy
IntegraGen announced today that it presented data on the company’s proprietary miR-31 (…) »
20 September 2018
IntegraGen Reports Financial Results for 1st Half of 2018
IntegraGen has announced today its financial results for the first half of semester 2018 with the accounts having been examined by the company’s Board of Directors on September 20, 2018.
Sales revenue: 3.7 M€, +17% vs. H1 2017 Significant growth in genomics services Operating profit: -0.5 M€, + 57% vs. (…) »19 September 2018
IntegraGen nominated for a 2018 PrixGalien MedStartup Award
IntegraGen has been nominated for a 2018 PrixGalien MedStartup Award, a joint initiative between The Galien Foundation and Business France to encourage and reward international partnerships between French and North American innovators in the Life Sciences Industry. IntegraGen was selected as a nominee by an (…) »
